Nura Bio Bolsters Leadership with New CMO and CBO for Clinical Expansion
Nura Bio, Inc. (Nura Bio), a clinical-stage biopharmaceutical company focused on developing neuroprotective small molecule therapies for debilitating neurological diseases, has announced the appointments of Dr. Lahar Mehta as Chief Medical Officer and Scott Greenberg as Chief Business Officer. Both will play pivotal roles in advancing Nura Bio’s clinical pipeline across various neurological conditions.
“At Nura Bio, we have made significant progress in developing our company and pipeline,” said Shilpa Sambashivan, Ph.D., Nura Bio CEO. “We are delighted to have Lahar and Scott join our team as we enter the company’s next phase of expansion and clinical development. They will both play critical roles as we evaluate our lead SARM1 inhibitor, NB-4746, in a patient population while continuing to advance our promising preclinical pipeline”.
Lahar Mehta, M.D., joins Nura Bio from Amylyx Pharmaceuticals, where he was Senior Vice President/Head, Global Clinical Development, leading clinical development and clinical pharmacology activities across several indications including amyotrophic lateral sclerosis (ALS), progressive supranuclear palsy (PSP), and Wolfram syndrome. Lahar’s clinical development experience spans several neurological indications such as multiple sclerosis, stroke, and migraine across multiple companies including Biogen, Amgen, and Annexon Biosciences.
Lahar earned his undergraduate degree from Washington University in St. Louis and his medical degree from Meharry Medical College, Nashville, following which he served as a General Medical Officer with the United States Navy. Lahar completed his neurology residency at the University of Utah and a fellowship in Neuroimmunology and Experimental Therapeutics at the University of Rochester.
Scott Greenberg joins Nura Bio with over 20 years of experience in business development, R&D strategy, and management across various therapeutic areas. Before this, he was the Chief Operating Officer at Aro Biotherapeutics, a biotech firm focused on targeted siRNA therapies. There, he led fundraising, finance, business development, corporate strategy, new product planning, and project management efforts.